Complement and coagulation in B. anthracis peptidoglycan-induced sepsis

Information

  • Research Project
  • 10237857
  • ApplicationId
    10237857
  • Core Project Number
    U19AI062629
  • Full Project Number
    5U19AI062629-18
  • Serial Number
    062629
  • FOA Number
    RFA-AI-17-040
  • Sub Project Id
    7838
  • Project Start Date
    9/15/2004 - 20 years ago
  • Project End Date
    8/31/2024 - 5 months ago
  • Program Officer Name
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    18
  • Suffix
  • Award Notice Date
    8/13/2021 - 3 years ago

Complement and coagulation in B. anthracis peptidoglycan-induced sepsis

Project Summary Our work demonstrates that peptidoglycan (PGN), a major component of the cell wall of all Gram-positive bacteria, promotes inflammation and coagulation. Baboons responded to in vivo PGN challenge with features of systemic inflammation and disseminated intravascular coagulopathy (DIC) similar to those seen in patients with inhalation anthrax. We found evidence of activation of both the intrinsic and extrinsic coagulation pathways. In vitro, we found PGN stimulated robust cytokine production in human innate immune cells and prothrombinase activity in human platelets exposed to highly purified polymeric PGN derived from B. anthracis or Staphylococcus aureus. Innate immune cell responses required PGN recognition by surface Fc? receptors, phagocytosis, digestion in lysosomes, and stimulation of cytoplasmic NOD sensors. In the last iteration of this grant, we showed that these processes were dependent on human serum opsonins, IgG and serum amyloid P. We also showed that PGN-stimulated human monocytes expressed tissue factor (TF), an initiator of the extrinsic coagulation pathway, in part by virtue of the proinflammatory cytokines. This project will provide mechanistic insight into PGN-stimulated pathologies. First, we will test whether and how the anthrax toxins affect the immune system activation events we have documented to date and listed above. Second, we will identify the pathways that regulate PGN-induced activation of the intrinsic coagulation pathway in vivo. Lastly, we will apply existing biological inhibitors to each pathway (intrinsic, extrinsic coagulation and complement) to ask which of these contributes most to the pathology, organ failure and death in PGN-challenged animals. The results will greatly inform treatment options for patients with Gram-positive bacteremia.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U19
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    260000
  • Indirect Cost Amount
    194480
  • Total Cost
  • Sub Project Total Cost
    454480
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAID:454480\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OKLAHOMA MEDICAL RESEARCH FOUNDATION
  • Organization Department
  • Organization DUNS
    077333797
  • Organization City
    OKLAHOMA CITY
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    731045005
  • Organization District
    UNITED STATES